147 related articles for article (PubMed ID: 38649595)
1. CROCuS, a Phase II Study Evaluating the Antiviral Activity, Clinical Outcomes, and Safety of Rilematovir in Children Aged ≥ 28 Days and ≤ 3 Years with Acute Respiratory Tract Infection Due to Respiratory Syncytial Virus.
Ferrero F; Lin CY; Liese J; Luz K; Stoeva T; Nemeth A; Gijón M; Calvo C; Natalini S; Toh TH; Deleu S; Chen B; Rusch S; Sánchez BL; Leipoldt I; Vijgen L; Huntjens D; Baguet T; Bertzos K; Gamil M; Stevens M;
Paediatr Drugs; 2024 Jul; 26(4):411-427. PubMed ID: 38649595
[TBL] [Abstract][Full Text] [Related]
2. A pilot phase 2a, randomized, double-blind, placebo-controlled study to explore the antiviral activity, clinical outcomes, safety, and tolerability of rilematovir at two dose levels in non-hospitalized adults with respiratory syncytial virus infection.
Nilsson AC; Pullman J; Napora P; Luz K; Gupta A; Draghi J; Guzman Romero AK; Aggarwal N; Petrova G; Ianus J; Vijgen L; Scott J; Sinha R; Rusch S; Huntjens D; Bertzos K; Stevens M;
Clin Microbiol Infect; 2023 Oct; 29(10):1320-1327. PubMed ID: 37422079
[TBL] [Abstract][Full Text] [Related]
3. Nebulised ALX-0171 for respiratory syncytial virus lower respiratory tract infection in hospitalised children: a double-blind, randomised, placebo-controlled, phase 2b trial.
Cunningham S; Piedra PA; Martinon-Torres F; Szymanski H; Brackeva B; Dombrecht E; Detalle L; Fleurinck C;
Lancet Respir Med; 2021 Jan; 9(1):21-32. PubMed ID: 33002427
[TBL] [Abstract][Full Text] [Related]
4. A Randomized, Placebo-Controlled, Respiratory Syncytial Virus Human Challenge Study of the Antiviral Efficacy, Safety, and Pharmacokinetics of RV521, an Inhibitor of the RSV-F Protein.
DeVincenzo J; Tait D; Efthimiou J; Mori J; Kim YI; Thomas E; Wilson L; Harland R; Mathews N; Cockerill S; Powell K; Littler E
Antimicrob Agents Chemother; 2020 Jan; 64(2):. PubMed ID: 31712214
[TBL] [Abstract][Full Text] [Related]
5. Activity of Oral ALS-008176 in a Respiratory Syncytial Virus Challenge Study.
DeVincenzo JP; McClure MW; Symons JA; Fathi H; Westland C; Chanda S; Lambkin-Williams R; Smith P; Zhang Q; Beigelman L; Blatt LM; Fry J
N Engl J Med; 2015 Nov; 373(21):2048-58. PubMed ID: 26580997
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics, Safety, and Antiviral Effects of Multiple Doses of the Respiratory Syncytial Virus (RSV) Fusion Protein Inhibitor, JNJ-53718678, in Infants Hospitalized With RSV Infection: A Randomized Phase 1b Study.
Martinón-Torres F; Rusch S; Huntjens D; Remmerie B; Vingerhoets J; McFadyen K; Ferrero F; Baraldi E; Rojo P; Epalza C; Stevens M
Clin Infect Dis; 2020 Dec; 71(10):e594-e603. PubMed ID: 32201897
[TBL] [Abstract][Full Text] [Related]
7. EDP-938, a Respiratory Syncytial Virus Inhibitor, in a Human Virus Challenge.
Ahmad A; Eze K; Noulin N; Horvathova V; Murray B; Baillet M; Grey L; Mori J; Adda N
N Engl J Med; 2022 Feb; 386(7):655-666. PubMed ID: 35172056
[TBL] [Abstract][Full Text] [Related]
8. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
9. A Phase 2b, Randomized, Double-blind, Placebo-Controlled Multicenter Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of Presatovir in Hematopoietic Cell Transplant Recipients with Respiratory Syncytial Virus Infection of the Lower Respiratory Tract.
Marty FM; Chemaly RF; Mullane KM; Lee DG; Hirsch HH; Small CB; Bergeron A; Shoham S; Ljungman P; Waghmare A; Blanchard E; Kim YJ; McKevitt M; Porter DP; Jordan R; Guo Y; German P; Boeckh M; Watkins TR; Chien JW; Dadwal SS
Clin Infect Dis; 2020 Dec; 71(11):2787-2795. PubMed ID: 31915807
[TBL] [Abstract][Full Text] [Related]
10. Oral GS-5806 activity in a respiratory syncytial virus challenge study.
DeVincenzo JP; Whitley RJ; Mackman RL; Scaglioni-Weinlich C; Harrison L; Farrell E; McBride S; Lambkin-Williams R; Jordan R; Xin Y; Ramanathan S; O'Riordan T; Lewis SA; Li X; Toback SL; Lin SL; Chien JW
N Engl J Med; 2014 Aug; 371(8):711-22. PubMed ID: 25140957
[TBL] [Abstract][Full Text] [Related]
11. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
12. Antiviral Activity of Oral JNJ-53718678 in Healthy Adult Volunteers Challenged With Respiratory Syncytial Virus: A Placebo-Controlled Study.
Stevens M; Rusch S; DeVincenzo J; Kim YI; Harrison L; Meals EA; Boyers A; Fok-Seang J; Huntjens D; Lounis N; Mari N K; Remmerie B; Roymans D; Koul A; Verloes R
J Infect Dis; 2018 Jul; 218(5):748-756. PubMed ID: 29684148
[TBL] [Abstract][Full Text] [Related]
13. Motavizumab treatment of infants hospitalized with respiratory syncytial virus infection does not decrease viral load or severity of illness.
Ramilo O; Lagos R; Sáez-Llorens X; Suzich J; Wang CK; Jensen KM; Harris BS; Losonsky GA; Griffin MP;
Pediatr Infect Dis J; 2014 Jul; 33(7):703-9. PubMed ID: 24356256
[TBL] [Abstract][Full Text] [Related]
14. A Phase 1 Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Safety, Tolerability, and Pharmacokinetics of a Respiratory Syncytial Virus Neutralizing Monoclonal Antibody MK-1654 in Healthy Adults.
Aliprantis AO; Wolford D; Caro L; Maas BM; Ma H; Montgomery DL; Sterling LM; Hunt A; Cox KS; Vora KA; Roadcap BA; Railkar RA; Lee AW; Stoch SA; Lai E
Clin Pharmacol Drug Dev; 2021 May; 10(5):556-566. PubMed ID: 33125189
[TBL] [Abstract][Full Text] [Related]
15. Safety and pharmacokinetics of palivizumab therapy in children hospitalized with respiratory syncytial virus infection.
Sáez-Llorens X; Moreno MT; Ramilo O; Sánchez PJ; Top FH; Connor EM;
Pediatr Infect Dis J; 2004 Aug; 23(8):707-12. PubMed ID: 15295219
[TBL] [Abstract][Full Text] [Related]
16. A Phase 2, Randomized, Double-blind, Placebo-Controlled Trial of Presatovir for the Treatment of Respiratory Syncytial Virus Upper Respiratory Tract Infection in Hematopoietic-Cell Transplant Recipients.
Chemaly RF; Dadwal SS; Bergeron A; Ljungman P; Kim YJ; Cheng GS; Pipavath SN; Limaye AP; Blanchard E; Winston DJ; Stiff PJ; Zuckerman T; Lachance S; Rahav G; Small CB; Mullane KM; Patron RL; Lee DG; Hirsch HH; Waghmare A; McKevitt M; Jordan R; Guo Y; German P; Porter DP; Gossage DL; Watkins TR; Marty FM; Chien JW; Boeckh M
Clin Infect Dis; 2020 Dec; 71(11):2777-2786. PubMed ID: 31793991
[TBL] [Abstract][Full Text] [Related]
17. Azithromycin Treatment vs Placebo in Children With Respiratory Syncytial Virus-Induced Respiratory Failure: A Phase 2 Randomized Clinical Trial.
Kong M; Zhang WW; Sewell K; Gorman G; Kuo HC; Aban I; Ambalavanan N; Whitley RJ
JAMA Netw Open; 2020 Apr; 3(4):e203482. PubMed ID: 32324238
[TBL] [Abstract][Full Text] [Related]
18. Respiratory syncytial virus (RSV) immune globulin intravenous therapy for RSV lower respiratory tract infection in infants and young children at high risk for severe RSV infections: Respiratory Syncytial Virus Immune Globulin Study Group.
Rodriguez WJ; Gruber WC; Welliver RC; Groothuis JR; Simoes EA; Meissner HC; Hemming VG; Hall CB; Lepow ML; Rosas AJ; Robertsen C; Kramer AA
Pediatrics; 1997 Mar; 99(3):454-61. PubMed ID: 9041304
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of motavizumab for the prevention of respiratory syncytial virus disease in healthy Native American infants: a phase 3 randomised double-blind placebo-controlled trial.
O'Brien KL; Chandran A; Weatherholtz R; Jafri HS; Griffin MP; Bellamy T; Millar EV; Jensen KM; Harris BS; Reid R; Moulton LH; Losonsky GA; Karron RA; Santosham M;
Lancet Infect Dis; 2015 Dec; 15(12):1398-408. PubMed ID: 26511956
[TBL] [Abstract][Full Text] [Related]
20. Immunoglobulin treatment for hospitalised infants and young children with respiratory syncytial virus infection.
Sanders SL; Agwan S; Hassan M; van Driel ML; Del Mar CB
Cochrane Database Syst Rev; 2019 Aug; 8(8):CD009417. PubMed ID: 31446622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
